Trial reportBone marrow transplantation2016
The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation.
Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 131 citations in OpenAlex.
- A Randomized Clinical Trial Evaluating Lactiplantibacillus Plantarum for the Prevention of GI aGvHD: A Report From the Children's Oncology Group (ACCL1633).Transplantation and cellular therapy · 2025Trial
- The effect of an acute aspirin challenge on intestinal permeability in healthy adults with and without prophylactic probiotic consumption: a double-blind, placebo-controlled, randomized trial.BMC gastroenterology · 2024Trial
- The intestinal microbiota as a key modulator of acute graft-versus-host disease.Nature reviews. Cancer · 2026Review
- The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities.Nutrients · 2026Review
- Personalizing Nutritional Therapy in Pediatric Oncology: The Role of Gut Microbiome Profiling and Metabolomics in Mitigating Mucositis and Enhancing Immune Response to Chemotherapy.Children (Basel, Switzerland) · 2026Review
- The gut-bone marrow axis in acute leukemia: an evidence-graded review of microbiota-immune crosstalk and therapeutic implications.Frontiers in cellular and infection microbiology · 2026Review
- Pathophysiology, evaluation, and management of malnutrition in hematologic malignancies: a comprehensive review.Frontiers in nutrition · 2026Review
- Current state of microbiota clinical applications in neonatal and pediatric bacterial infections.Gut microbes · 2025Review
- Gut Microbiome and its Impact on Outcomes following Hematopoietic Stem Cell Transplantation: a Comprehensive Review.Stem cell reviews and reports · 2025Review
- "The microbiome in graft-versus-host disease: a tale of two ecosystems".Journal of translational medicine · 2025Review
- The Impact of Health-Promoting Lifestyle Behaviors on Gut Microbiota in Survivors of Hematological Cancer: A Scoping Review.Cancer reports (Hoboken, N.J.) · 2025Article
- Impact of ExogenousAntibiotics (Basel, Switzerland) · 2024Article
- Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease.Blood · 2024Review
- The Microbiome and Pediatric Transplantation.Journal of the Pediatric Infectious Diseases Society · 2024Review
- The Role of Probiotics in the Prevention ofNutrients · 2024Review
- Gut microbiota, microbiota-derived metabolites, and graft-versus-host disease.Cancer medicine · 2024Review
- Research advances on short-chain fatty acids in gastrointestinal acute graft-Therapeutic advances in hematology · 2024Review
- Review
- Intestinal barrier functions in hematologic and oncologic diseases.Journal of translational medicine · 2023Review
- The emerging role of nutritional support in the supportive care of pediatric patients undergoing hematopoietic stem cell transplantation.Frontiers in nutrition · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic cell transplantation (HCT) has become a standard treatment for many adult and pediatric conditions. Emerging evidence suggests that perturbations in the microbiota diversity increase recipients' susceptibilities to gut-mediated conditions such as diarrhea, infection and acute GvHD. Probiotics preserve the microbiota and may minimize the risk of developing a gut-mediated condition; however, their safety has not been evaluated in the setting of HCT. We evaluated the safety and feasibility of the probiotic, Lactobacillus plantarum (LBP), in children and adolescents undergoing allogeneic HCT. Participants received once-daily supplementation with LBP beginning on day -8 or -7 and continued until day +14. Outcomes were compliance with daily administration and incidence of LBP bacteremia. Administration of LBP was feasible with 97% (30/31, 95% confidence interval (CI) 83-100%) of children receiving at least 50% of the probiotic dose (median 97%; range 50-100%). We did not observe any case of LBP bacteremia (0% (0/30) with 95% CI 0-12%). There were not any unexpected adverse events related to LBP. Our study provides preliminary evidence that administration of LBP is safe and feasible in children and adolescents undergoing HCT. Future steps include the conduct of an approved randomized, controlled trial through Children's Oncology Group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.